Subsidy Information and Financing Scheme MAFNirmatrelvir & Ritonavir [Paxlovid] Tablets, Nirmatrelvir 150 mg + Ritonavir 100 mg Additional clinical criteria applies Treatment of mild-to-moderate Coronavirus Disease 2019 (COVID... See all × MAFNirmatrelvir & Ritonavir [Paxlovid] Tablets, Nirmatrelvir 150 mg + Ritonavir 100 mg Additional clinical criteria applies Treatment of mild-to-moderate Coronavirus Disease 2019 (COVID-19), within 5 days of symptom onset, in patients who are at high risk for progression to severe COVID-19, including hospitalisation or death.
Drug Guidance for Subsidy 25/10/2024 Nirmatrelvir and ritonavir combination for treating mild-to-moderate COVID-19 The Ministry of Health’s Drug Advisory Committee has recommended: Nirmatrelvir 150 mg tablet ... See all × 25/10/2024 Nirmatrelvir and ritonavir combination for treating mild-to-moderate COVID-19 The Ministry of Health’s Drug Advisory Committee has recommended: Nirmatrelvir 150 mg tablet and ritonavir 100 mg tablet combination for treating mild-to moderate Coronavirus Disease 2019 (COVID-19) in patients aged 18 years or older who are immunocompromised. Funding status RNirmatrelvir 150 mg tablet and ritonavir 100 mg tablet combination is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2024. RNirmatrelvir and ritonavir combination should be used in line with the additional clinical criteria listed in the Annex.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Paxlovid Tablets, Nirmatrelvir 150 mg + Ritonavir 100 mg Changi General Hospital Institute of Mental Health Khoo Teck Puat Hospital National Cancer Centre Sengkang General Hospital Singapore General Hospital Tan Tock Seng Hospital Woodlands Health Campus